CBD Headlines
Home » Archives for August 2021 » Page 3

Month: August 2021

FridayAug 06, 2021 9:00 am

RYAH Group Inc. (CSE: RYAH) Sees Important Trends in Sports Medicine and Plant-Therapy

As U.S. research restrictions are lifted there is a rising interest in the use of plant-therapy in sports medicine Cannabis in sports medicine took center stage at the Tokyo Olympics American athletes are turning more and more to cannabis as a pain reliever, alternative to opioids, and part of an overall sports recovery plan RYAH Group (CSE: RYAH) (formerly RYAH Medtech), the leader in dose-control technology for plant-based medicine, works with researchers to provide a full turnkey solution for clinical studies from start to finish. RYAH Group's dose-control devices standardize the dosing protocol, QR products ensure compliance, and mobile apps…

Continue Reading

ThursdayAug 05, 2021 1:16 pm

Grapefruit USA Inc. (GPFT) Signs Agreement with Leading Canadian Cannabis Manufacturer to Offer Game-Changing THC/CBD Cream

GPFT forms strategic alliance with 6PAK Solutions Inc Company working to achieve goal of launching Hourglass in Canada in the third quarter of 2021 Grapefruit’s patented Hourglass delivery cream system has fundamentally changed the way humans absorb cannabinoids In the United States, Grapefruit USA (OTCQB: GPFT) provides consumers with one of the most effective cannabis topical creams on the market. Now, through its partnership with 6PAK Solutions Inc., Grapefruit can offer its patented Hourglass(TM) Time Release THC+CBD Delivery Topical Relief Cream in Canada too (https://cnw.fm/qeAd5).  “We are very encouraged by 6PAK’s decision to form an alliance with Grapefruit to take…

Continue Reading

WednesdayAug 04, 2021 12:05 pm

Grapefruit USA Inc. (GPFT) Expands into Billion-Dollar Market with New CBD Pet Tincture

Pet CBD industry projected to reach $1.7 billion by 2025 GPFT’s new pet CBD product targets two common dog, cat ailments: anxiety and joint pain Pets deserve the same relief that their owners experience with Grapefruit’s CBD products, says CEO Humans aren’t the only ones who may benefit from all that cannabidiol (“CBD”) offers. A recent Brightfield Group article reported that the pet CBD industry has experienced significant growth over the last several years, with Brightfield projecting an expected market valuation of more than $1.7 billion by 2025 (https://cnw.fm/drv6i). Grapefruit USA (OTCQB: GPFT) is leveraging its expertise in the space…

Continue Reading

WednesdayAug 04, 2021 11:11 am

RYAH Group Inc. (CSE: RYAH) Supporting U.S. Changes in Cannabis Research

New cultivators have approved for federally funded studies in the U.S., and 575 DEA-licensed researchers are standing by, ready for the change RYAH's ecosystem of products allows data to be collected from seed to consumption, providing a holistic view of the plant necessary for optimal research RYAH continues to expand its global clinical and distribution network for plant-based medicine and digital patient care  The U.S. is putting an end to its 50-year long prohibition on Cannabis Research (https://cnw.fm/UOoHf). New cultivators have now been approved for federally funded studies. With over 575 DEA-licensed researchers across the U.S., the future of cannabis…

Continue Reading

TuesdayAug 03, 2021 9:30 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Is ‘One to Watch’

InMed has a world class leadership team with a successful track record of drug development and commercialization The company recently announced closing of a $12 million private placement InMed has a solid and expanding intellectual property portfolio with multiple patents filed The company recently signed an LOI to acquire rare cannabinoids manufacturer BayMedica InMed retains all commercial rights to its IntegraSyn manufacturing system InMed has filed clinical trial applications in several countries as part of a Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa The consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to…

Continue Reading

MondayAug 02, 2021 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Steadily Achieving Its Operational and Business Plan Objectives

Lexaria just completed dosing for its second human clinical study, HYPER-H21-2  The study sought to understand the human response to Lexaria’s DehydraTECH 2.0-enabled CBD The company also announced that its DehydraTECH-enabled consumer products are available for purchase in over 7,000 stores across the United States Lexaria also expanded its intellectual property portfolio with the allowance of its second patent in Japan It also received US$3,817,643 from warrant exercises, proceeds from which will be used to advance the company’s research and development program and for its general corporate purposes Lexaria Bioscience (NASDAQ: LEXX) has been making incredible strides in 2021 as…

Continue Reading

CBDWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000

CBDWire

1108 Lavaca St
Suite 110-CBDW
Austin, TX 78701
(512) 354-7000

Copyright © . CBDWire / 1108 Lavaca St Suite 110-CBDW Austin, TX 78701 (512) 354-7000 / Disclaimers